Balmaņa, Judith <br/><br/>
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.  [electronic resource] 

 -  Cancer discovery  Jun 2011 
 - 29-34 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>2159-8290 
<br/><br/><label>Standard No.: </label>10.1158/2159-8274.CD-11-0048  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>BRCA1 Protein--metabolism<br/>BRCA2 Protein--metabolism<br/>Breast Neoplasms--drug therapy<br/>Clinical Trials, Phase I as Topic<br/>Clinical Trials, Phase II as Topic<br/>Drug Evaluation, Preclinical<br/>Humans<br/>Molecular Targeted Therapy--methods<br/>Poly(ADP-ribose) Polymerase Inhibitors<br/>Poly(ADP-ribose) Polymerases--metabolism<br/>Precision Medicine--methods